Heron Therapeutics, Inc.
HRTX
$2.11
-$0.06-2.77%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 90.38% | 87.72% | 76.64% | 64.77% | 46.36% |
| Total Depreciation and Amortization | -17.98% | -14.04% | -11.73% | -6.16% | -0.55% |
| Total Amortization of Deferred Charges | 141.12% | 183.48% | 264.60% | 153.66% | 110.84% |
| Total Other Non-Cash Items | -46.38% | -52.11% | -54.89% | -51.39% | -30.70% |
| Change in Net Operating Assets | -542.49% | -264.40% | 95.74% | 109.62% | 137.93% |
| Cash from Operations | 49.58% | 61.68% | 91.60% | 83.54% | 66.06% |
| Capital Expenditure | -37.40% | -10.42% | 22.88% | -74.82% | -31.44% |
| Sale of Property, Plant, and Equipment | 430.77% | 107.69% | 333.33% | -92.40% | -92.40% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 232.01% | 4.43% | -100.77% | -260.94% | -169.46% |
| Cash from Investing | 212.23% | 4.00% | -105.34% | -279.28% | -177.83% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.93% | -96.93% | -97.69% | -60.20% | -59.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 107.75% | 100.00% | 99.82% | 69.87% | 37.87% |
| Cash from Financing | -98.17% | -98.26% | -98.68% | -27.81% | -28.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.21% | -121.60% | 41.47% | 114.01% | 77.73% |